Polycystic ovary syndrome may get a new name, and researchers say it is overdue
Health·November 7, 2026
For decades, one of the most common hormonal conditions affecting people with ovaries has carried a name that many clinicians now consider misleading. Polycystic ovary syndrome, or PCOS, takes its name from cysts that show up on the ovaries, but many people who have the condition never develop them. An international group of researchers wants to change that, proposing a new label: polyendocrine metabolic ovarian syndrome, or PMOS.
In a recent episode of Scientific American's Science Quickly podcast, host Rachel Feltman spoke with physician Anuja Dokras, one of the researchers involved in the effort, about how the old name came to be and why it no longer fits. The conversation covered what the condition involves in practice, from hormone imbalances and irregular periods to metabolic changes such as how the body handles insulin. Those features reach well beyond the ovaries, which is the core reason the new name leans on the word "endocrine" and the idea of metabolism.
The proposal came out of a multistep global consensus process, documented in a paper in The Lancet published online on May 12, 2026. The paper is authored by Helena J. Teede and colleagues. Reaching agreement across specialists in different countries was not a quick exercise, and the group had to weigh how a new name would land with clinicians, researchers and patients who already know the condition by its current label.
The argument for the change is that a name shapes how people understand a diagnosis. A label centered on cysts can send patients and doctors looking for the wrong signs, and it can make a complex, whole-body condition sound like a problem limited to one organ. A more accurate name could help with recognition and conversation, though it will take time for medical guidelines, research and everyday usage to catch up.
For readers who have heard the term PCOS all their lives, the shift may feel abrupt. But the discussion around it reflects a broader trend in medicine, where researchers are revisiting old labels that no longer match the science. Whether PMOS sticks will depend on how quickly the rest of the medical community adopts it.